慢性纤维化及其向癌症的进展
Chronic Fibrosis and Its Progression to Cancer.
作者信息
Yasuma Taro, Gabazza Esteban C
机构信息
Department of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Mie, Japan.
出版信息
Int J Mol Sci. 2022 Apr 1;23(7):3924. doi: 10.3390/ijms23073924.
Abstract
The terminal stage of many chronic inflammatory diseases is organ fibrosis [...].
摘要
许多慢性炎症性疾病的终末期是器官纤维化[...]。
相似文献
1
Chronic Fibrosis and Its Progression to Cancer.慢性纤维化及其向癌症的进展
Int J Mol Sci. 2022 Apr 1;23(7):3924. doi: 10.3390/ijms23073924.
2
A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C.一种七基因特征（肝硬化风险评分）可预测初发轻度慢性丙型肝炎患者的肝纤维化进展。
Hepatology. 2009 Oct;50(4):1038-44. doi: 10.1002/hep.23111.
3
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.丙型肝炎病毒清除后，晚期纤维化患者肝硬化相关并发症的风险。
J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.
4
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.慢性丙型肝炎患者肝纤维化进展的自然史。OBSVIRC、METAVIR、CLINIVIR和DOSVIRC组。
Lancet. 1997 Mar 22;349(9055):825-32. doi: 10.1016/s0140-6736(96)07642-8.
5
Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C.丙型肝炎移植后供肝年龄增长与纤维化快速进展
Gut. 2002 Aug;51(2):248-52. doi: 10.1136/gut.51.2.248.
6
Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B.长期使用拉米夫定治疗可使慢性乙型肝炎患者的晚期肝纤维化/肝硬化病情出现好转。
J Gastroenterol Hepatol. 2015 Feb;30(2):372-8. doi: 10.1111/jgh.12718.
7
A comparison of fibrosis progression in chronic liver diseases.慢性肝病中纤维化进展的比较。
J Hepatol. 2003 Mar;38(3):257-65. doi: 10.1016/s0168-8278(02)00413-0.
8
Beyond scoring: a modern interpretation of disease progression in chronic liver disease.超越评分：慢性肝病疾病进展的现代解读
Gut. 2013 Sep;62(9):1234-41. doi: 10.1136/gutjnl-2012-302826. Epub 2013 May 5.
9
[Role of liver biopsy in the assessment of hepatic fibrosis--its utility and limitations].[肝活检在肝纤维化评估中的作用——其效用与局限性]
Korean J Hepatol. 2007 Jun;13(2):138-45.
10
Histopathological evaluation of liver fibrosis and cirrhosis regression.肝纤维化和肝硬化逆转的组织病理学评估。
Clin Mol Hepatol. 2017 Dec;23(4):302-307. doi: 10.3350/cmh.2017.0078. Epub 2017 Dec 20.
本文引用的文献
1
Molecular Mechanisms of Malignant Transformation of Oral Submucous Fibrosis by Different Betel Quid Constituents-Does Fibroblast Senescence Play a Role?不同槟榔成分致口腔黏膜下纤维性变恶性转化的分子机制——成纤维细胞衰老是否起作用？
Int J Mol Sci. 2022 Jan 31;23(3):1637. doi: 10.3390/ijms23031637.
2
MyD88 in myofibroblasts regulates aerobic glycolysis-driven hepatocarcinogenesis via ERK-dependent PKM2 nuclear relocalization and activation.肌成纤维细胞中的MyD88通过ERK依赖的PKM2核重新定位和激活来调节有氧糖酵解驱动的肝癌发生。
J Pathol. 2022 Apr;256(4):414-426. doi: 10.1002/path.5856. Epub 2022 Jan 27.
3
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development.从肺纤维化到肺癌发展的分子机制和细胞贡献。
Int J Mol Sci. 2021 Nov 10;22(22):12179. doi: 10.3390/ijms222212179.
4
Impact of Dietary Fat on the Progression of Liver Fibrosis: Lessons from Animal and Cell Studies.膳食脂肪对肝纤维化进展的影响：来自动物和细胞研究的启示。
Int J Mol Sci. 2021 Sep 24;22(19):10303. doi: 10.3390/ijms221910303.
5
Dendritic Cell and T Cell Crosstalk in Liver Fibrogenesis and Hepatocarcinogenesis: Implications for Prevention and Therapy of Liver Cancer.树突状细胞与 T 细胞在肝纤维化和肝癌发生中的相互作用：对肝癌预防和治疗的启示。
Int J Mol Sci. 2020 Oct 6;21(19):7378. doi: 10.3390/ijms21197378.
6
Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments.口腔黏膜下纤维性变：生物标志物、发病机制和治疗的综述。
Int J Mol Sci. 2020 Sep 30;21(19):7231. doi: 10.3390/ijms21197231.
7
Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.分子机制：非酒精性脂肪性肝病、脂肪性肝炎和肝细胞癌之间的联系。
Int J Mol Sci. 2020 Feb 23;21(4):1525. doi: 10.3390/ijms21041525.
8
Phenotypic Plasticity of Fibroblasts during Mammary Carcinoma Development.成纤维细胞在乳腺癌发展过程中的表型可塑性。
Int J Mol Sci. 2019 Sep 9;20(18):4438. doi: 10.3390/ijms20184438.
9
The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment.成纤维细胞的阴暗面：肿瘤微环境中作为免疫抑制介质的癌相关成纤维细胞。
Front Immunol. 2019 Aug 2;10:1835. doi: 10.3389/fimmu.2019.01835. eCollection 2019.
10
Myeloid-derived suppressor cells coming of age.髓系来源的抑制细胞崭露头角。
Nat Immunol. 2018 Feb;19(2):108-119. doi: 10.1038/s41590-017-0022-x. Epub 2018 Jan 18.
Zotero 插件